Early PSA response is an independent prognostic factor in patients with metastatic castration-resistant prostate cancer treated with next-generation androgen pathway inhibitors
详细信息 查看全文
- 作者：Alina Fuerea ; Giulia Baciarello ; Anna Patrikidou ; Laurence Albigè ; s ; Christophe Massard ; Mario Di Palma ; Bernard Escudier ; Karim Fizazi ; Yohann Loriot ; yohann.loriot@gustaveroussy.fr" class="auth_mail" title="E-mail the corresponding author
- 关键词：Prostate cancer ; PSA ; Enzalutamide ; Abiraterone
- 刊名：European Journal of Cancer
- 出版年：2016
- 出版时间：July 2016
- 年：2016
- 卷：61
- 期：Complete
- 页码：44-51
- 全文大小：512 K
文摘
- •
Early prostate-specific antigen (PSA) response defined as a decline >50% from baseline at day 28 is associated with better radiographic progression-free survival and overall survival (OS).
- •
Early PSA response (EPR) remained prognostic for OS in multivariate analyses that included validated pre-therapeutic prognostic factors for metastatic castration-resistant prostate cancer.
- •
Prognostic values of EPR for radiographic progression-free survival and OS were confirmed in an independent cohort of 95 abiraterone-treated non-trial patients.